Treatment for 1 year also seen to reduce levels of disease biomarkers
by |
One year of treatment with ALZ-801 (valiltramiprosate) was found in a Phase 2 trial to improve cognition and lower the levels of disease biomarkers among people with early Alzheimer’s with one or two copies of the apolipoprotein E4 (APOE4) disease-associated genetic variant.
Importantly, the investigational therapy from Alzheon did not cause certain side effects, such as brain swelling and bleeds, that have been sometimes linked to anti-amyloid antibody therapies — ones to which APOE4 carriers may be particularly susceptible.
The new findings were detailed by John A. Hey, PhD, chief scientific officer of Alzheon, in an oral presentation at the American Academy of Neurology (AAN) Conference, held April 22-27 in Boston and virtually.